Breast Cancer

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002

Key clinical point: Compared with whole breast irradiation (WBI), partial breast irradiation (PBI) led to a similar rate of ipsilateral breast recurrences (IBR) and demonstrated a better toxicity profile in patients with early-stage breast cancer (BC).

Major finding: Rate of IBR was comparable with PBI vs WBI at 5 years (relative risk [RR] 1.34; 95% CI 0.83-2.18) and 10 years (RR 1.29; 95% CI 0.87-1.91). Patients undergoing PBI vs WBI reported fewer acute adverse events (AE; incidence rate ratio [IRR] 0.53; 95% CI 0.31-0.92) and acute grade ≥2 AE (IRR 0.21; 95% CI 0.07-0.62).

Study details: Findings are from a meta-analysis of 14 randomized controlled trials and six comparative observational studies comparing any PBI modality with WBI in 17,234 adults with early-stage BC.

Disclosures: This study was supported by the US Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Shumway DA et al. Partial breast irradiation compared with whole breast irradiation: A systematic review and meta-analysis. J Natl Cancer Inst. 2023 (Jun 8). doi: 10.1093/jnci/djad100

Key clinical point: Compared with whole breast irradiation (WBI), partial breast irradiation (PBI) led to a similar rate of ipsilateral breast recurrences (IBR) and demonstrated a better toxicity profile in patients with early-stage breast cancer (BC).

Major finding: Rate of IBR was comparable with PBI vs WBI at 5 years (relative risk [RR] 1.34; 95% CI 0.83-2.18) and 10 years (RR 1.29; 95% CI 0.87-1.91). Patients undergoing PBI vs WBI reported fewer acute adverse events (AE; incidence rate ratio [IRR] 0.53; 95% CI 0.31-0.92) and acute grade ≥2 AE (IRR 0.21; 95% CI 0.07-0.62).

Study details: Findings are from a meta-analysis of 14 randomized controlled trials and six comparative observational studies comparing any PBI modality with WBI in 17,234 adults with early-stage BC.

Disclosures: This study was supported by the US Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Shumway DA et al. Partial breast irradiation compared with whole breast irradiation: A systematic review and meta-analysis. J Natl Cancer Inst. 2023 (Jun 8). doi: 10.1093/jnci/djad100

Key clinical point: Compared with whole breast irradiation (WBI), partial breast irradiation (PBI) led to a similar rate of ipsilateral breast recurrences (IBR) and demonstrated a better toxicity profile in patients with early-stage breast cancer (BC).

Major finding: Rate of IBR was comparable with PBI vs WBI at 5 years (relative risk [RR] 1.34; 95% CI 0.83-2.18) and 10 years (RR 1.29; 95% CI 0.87-1.91). Patients undergoing PBI vs WBI reported fewer acute adverse events (AE; incidence rate ratio [IRR] 0.53; 95% CI 0.31-0.92) and acute grade ≥2 AE (IRR 0.21; 95% CI 0.07-0.62).

Study details: Findings are from a meta-analysis of 14 randomized controlled trials and six comparative observational studies comparing any PBI modality with WBI in 17,234 adults with early-stage BC.

Disclosures: This study was supported by the US Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Shumway DA et al. Partial breast irradiation compared with whole breast irradiation: A systematic review and meta-analysis. J Natl Cancer Inst. 2023 (Jun 8). doi: 10.1093/jnci/djad100

Key clinical point: Targeted axillary dissection (TAD) after neoadjuvant systemic therapy was oncologically safe and led to excellent clinical outcomes in patients with node-positive early breast cancer (BC) who did not undergo axillary lymph node dissection (ALND).

Major finding: TAD alone vs TAD plus ALND was not associated with a higher risk for invasive disease-free survival (adjusted hazard ratio [aHR] 0.83; P = .69) and overall survival (aHR 1.07; P = .91).

Study details: Findings are from a cohort study including 199 patients with clinical stage T1-T4, node-positive early BC without distant metastases who underwent TAD with (40.2%) or without (59.8%) further axillary surgery.

Disclosures: The clips used to mark the targeted lymph nodes were provided for free by Tumark Vision (SOMATEX) and O-Twist (BIP). The authors declared receiving personal fees, honoraria, research funding, or other nonfinancial supports from various sources.

Source: Kuemmel S et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023 (Jun 7). doi: 10.1001/jamasurg.2023.1772

Key clinical point: Targeted axillary dissection (TAD) after neoadjuvant systemic therapy was oncologically safe and led to excellent clinical outcomes in patients with node-positive early breast cancer (BC) who did not undergo axillary lymph node dissection (ALND).

Major finding: TAD alone vs TAD plus ALND was not associated with a higher risk for invasive disease-free survival (adjusted hazard ratio [aHR] 0.83; P = .69) and overall survival (aHR 1.07; P = .91).

Study details: Findings are from a cohort study including 199 patients with clinical stage T1-T4, node-positive early BC without distant metastases who underwent TAD with (40.2%) or without (59.8%) further axillary surgery.

Disclosures: The clips used to mark the targeted lymph nodes were provided for free by Tumark Vision (SOMATEX) and O-Twist (BIP). The authors declared receiving personal fees, honoraria, research funding, or other nonfinancial supports from various sources.

Source: Kuemmel S et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023 (Jun 7). doi: 10.1001/jamasurg.2023.1772

Key clinical point: Targeted axillary dissection (TAD) after neoadjuvant systemic therapy was oncologically safe and led to excellent clinical outcomes in patients with node-positive early breast cancer (BC) who did not undergo axillary lymph node dissection (ALND).

Major finding: TAD alone vs TAD plus ALND was not associated with a higher risk for invasive disease-free survival (adjusted hazard ratio [aHR] 0.83; P = .69) and overall survival (aHR 1.07; P = .91).

Study details: Findings are from a cohort study including 199 patients with clinical stage T1-T4, node-positive early BC without distant metastases who underwent TAD with (40.2%) or without (59.8%) further axillary surgery.

Disclosures: The clips used to mark the targeted lymph nodes were provided for free by Tumark Vision (SOMATEX) and O-Twist (BIP). The authors declared receiving personal fees, honoraria, research funding, or other nonfinancial supports from various sources.

Source: Kuemmel S et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023 (Jun 7). doi: 10.1001/jamasurg.2023.1772

Key clinical point: In addition to switching endocrine therapy (ET), continuing the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with ribociclib therapy vs placebo demonstrated progression-free survival (PFS) benefits in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC) who had progressed on previous ET and CDK4/6i.

Major finding: At a median follow-up of 18.2 months, a significant improvement in PFS was observed in the ET+ribociclib+CDK4/6i vs ET+placebo group (hazard ratio 0.57; P = .006). ET+ribociclib+CDK4/6i demonstrated a manageable safety profile.

Study details: Findings are from the phase 2 MAINTAIN trial including 119 patients with HR+/HER2− metastatic BC who progressed on ET and CDK4/6i and were randomly assigned to receive a different ET with ribociclib plus CDK4/6i or placebo.

Disclosures: This study was supported by Novartis Pharmaceuticals and other sources. The authors declared no conflicts of interest.

Source: Kalinsky K et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023 (May 19). doi: 10.1200/JCO.22.02392

Key clinical point: In addition to switching endocrine therapy (ET), continuing the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with ribociclib therapy vs placebo demonstrated progression-free survival (PFS) benefits in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC) who had progressed on previous ET and CDK4/6i.

Major finding: At a median follow-up of 18.2 months, a significant improvement in PFS was observed in the ET+ribociclib+CDK4/6i vs ET+placebo group (hazard ratio 0.57; P = .006). ET+ribociclib+CDK4/6i demonstrated a manageable safety profile.

Study details: Findings are from the phase 2 MAINTAIN trial including 119 patients with HR+/HER2− metastatic BC who progressed on ET and CDK4/6i and were randomly assigned to receive a different ET with ribociclib plus CDK4/6i or placebo.

Disclosures: This study was supported by Novartis Pharmaceuticals and other sources. The authors declared no conflicts of interest.

Source: Kalinsky K et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023 (May 19). doi: 10.1200/JCO.22.02392

Key clinical point: In addition to switching endocrine therapy (ET), continuing the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with ribociclib therapy vs placebo demonstrated progression-free survival (PFS) benefits in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC) who had progressed on previous ET and CDK4/6i.

Major finding: At a median follow-up of 18.2 months, a significant improvement in PFS was observed in the ET+ribociclib+CDK4/6i vs ET+placebo group (hazard ratio 0.57; P = .006). ET+ribociclib+CDK4/6i demonstrated a manageable safety profile.

Study details: Findings are from the phase 2 MAINTAIN trial including 119 patients with HR+/HER2− metastatic BC who progressed on ET and CDK4/6i and were randomly assigned to receive a different ET with ribociclib plus CDK4/6i or placebo.

Disclosures: This study was supported by Novartis Pharmaceuticals and other sources. The authors declared no conflicts of interest.

Source: Kalinsky K et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023 (May 19). doi: 10.1200/JCO.22.02392

Key clinical point: Dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, plus letrozole or anastrozole demonstrated progression-free survival (PFS) benefits and a manageable safety profile in untreated patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: A 12.4-month improvement in PFS was observed with dalpiciclib vs placebo, with both letrozole and anastrozole (stratified hazard ratio 0.51; P < .0001). Dalpiciclib plus letrozole or anastrozole demonstrated a manageable safety profile, with similar proportions of patients in the dalpiciclib and placebo groups (4% and 2%, respectively) discontinuing the treatment.

Study details: Findings are from the phase 3 DAWNA-2 study including 456 patients with HR+/HER2− advanced BC who were randomly assigned to receive either letrozole or anastrozole with dalpiciclib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals and partly by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Three authors declared being employees of Hengrui, and Binghe Xu declared receiving research grants and fees from some sources.

Source: Zhang P et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646-657 (May 11). doi: 10.1016/S1470-2045(23)00172-9

Key clinical point: Dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, plus letrozole or anastrozole demonstrated progression-free survival (PFS) benefits and a manageable safety profile in untreated patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: A 12.4-month improvement in PFS was observed with dalpiciclib vs placebo, with both letrozole and anastrozole (stratified hazard ratio 0.51; P < .0001). Dalpiciclib plus letrozole or anastrozole demonstrated a manageable safety profile, with similar proportions of patients in the dalpiciclib and placebo groups (4% and 2%, respectively) discontinuing the treatment.

Study details: Findings are from the phase 3 DAWNA-2 study including 456 patients with HR+/HER2− advanced BC who were randomly assigned to receive either letrozole or anastrozole with dalpiciclib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals and partly by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Three authors declared being employees of Hengrui, and Binghe Xu declared receiving research grants and fees from some sources.

Source: Zhang P et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646-657 (May 11). doi: 10.1016/S1470-2045(23)00172-9

Key clinical point: Dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, plus letrozole or anastrozole demonstrated progression-free survival (PFS) benefits and a manageable safety profile in untreated patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: A 12.4-month improvement in PFS was observed with dalpiciclib vs placebo, with both letrozole and anastrozole (stratified hazard ratio 0.51; P < .0001). Dalpiciclib plus letrozole or anastrozole demonstrated a manageable safety profile, with similar proportions of patients in the dalpiciclib and placebo groups (4% and 2%, respectively) discontinuing the treatment.

Study details: Findings are from the phase 3 DAWNA-2 study including 456 patients with HR+/HER2− advanced BC who were randomly assigned to receive either letrozole or anastrozole with dalpiciclib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals and partly by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Three authors declared being employees of Hengrui, and Binghe Xu declared receiving research grants and fees from some sources.

Source: Zhang P et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646-657 (May 11). doi: 10.1016/S1470-2045(23)00172-9

Key clinical point: The combination of apatinib and etoposide proved to be a feasible treatment option for patients with triple-negative breast cancer (TNBC) who had failed ≥1 line of chemotherapy in the advanced setting.

Major finding: The median progression-free survival and overall survival were 6.0 and 24.5 months, respectively, with an objective response rate of 10.0% and a disease control rate of 62.5%. Overall, 95.0% of patients experienced adverse events (AE) of any grade, mostly grade 1 and 2. Hypertension (65.0%), nausea (47.5%), vomiting (42.5%), and hand-foot syndrome (32.5%) were the most common AE.

Study details: Findings are from a single-arm phase 2 study including 40 patients with advanced TNBC who had failed ≥1 line of chemotherapy and received oral apatinib plus oral etoposide.

Disclosures: This study was funded by National Cancer Fund Climbing Fund. The authors declared no conflicts of interest.

Source: Cao M et al. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: A phase II trial. BMC Cancer. 2023;23:463 (May 19). doi: 10.1186/s12885-023-10768-8

Key clinical point: The combination of apatinib and etoposide proved to be a feasible treatment option for patients with triple-negative breast cancer (TNBC) who had failed ≥1 line of chemotherapy in the advanced setting.

Major finding: The median progression-free survival and overall survival were 6.0 and 24.5 months, respectively, with an objective response rate of 10.0% and a disease control rate of 62.5%. Overall, 95.0% of patients experienced adverse events (AE) of any grade, mostly grade 1 and 2. Hypertension (65.0%), nausea (47.5%), vomiting (42.5%), and hand-foot syndrome (32.5%) were the most common AE.

Study details: Findings are from a single-arm phase 2 study including 40 patients with advanced TNBC who had failed ≥1 line of chemotherapy and received oral apatinib plus oral etoposide.

Disclosures: This study was funded by National Cancer Fund Climbing Fund. The authors declared no conflicts of interest.

Source: Cao M et al. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: A phase II trial. BMC Cancer. 2023;23:463 (May 19). doi: 10.1186/s12885-023-10768-8

Key clinical point: The combination of apatinib and etoposide proved to be a feasible treatment option for patients with triple-negative breast cancer (TNBC) who had failed ≥1 line of chemotherapy in the advanced setting.

Major finding: The median progression-free survival and overall survival were 6.0 and 24.5 months, respectively, with an objective response rate of 10.0% and a disease control rate of 62.5%. Overall, 95.0% of patients experienced adverse events (AE) of any grade, mostly grade 1 and 2. Hypertension (65.0%), nausea (47.5%), vomiting (42.5%), and hand-foot syndrome (32.5%) were the most common AE.

Study details: Findings are from a single-arm phase 2 study including 40 patients with advanced TNBC who had failed ≥1 line of chemotherapy and received oral apatinib plus oral etoposide.

Disclosures: This study was funded by National Cancer Fund Climbing Fund. The authors declared no conflicts of interest.

Source: Cao M et al. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: A phase II trial. BMC Cancer. 2023;23:463 (May 19). doi: 10.1186/s12885-023-10768-8

Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).

Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).

Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.

Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689

Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).

Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).

Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.

Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689

Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).

Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).

Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.

Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689

Key clinical point: Aspirin intake may be associated with a reduced risk for incident breast cancer (BC) in adults.

Major finding: Aspirin users vs nonusers had a significantly reduced risk for BC (hazard ratio [HR] 0.91; P =  .002), especially estrogen receptor-positive BC (HR 0.90; P = .0004).

Study details: Findings are from a meta-analysis of 28 cohort studies including adults who received aspirin.

Disclosures: This study did not report the funding source. The authors declared no conflicts of interest.

Source: Bakierzynska M et al. Prophylactic aspirin intake and breast cancer risk: A systematic review and meta-analysis of observational cohort studies. Eur J Surg Oncol. 2023 (Jun 6). doi: 10.1016/j.ejso.2023.05.015

Key clinical point: Aspirin intake may be associated with a reduced risk for incident breast cancer (BC) in adults.

Major finding: Aspirin users vs nonusers had a significantly reduced risk for BC (hazard ratio [HR] 0.91; P =  .002), especially estrogen receptor-positive BC (HR 0.90; P = .0004).

Study details: Findings are from a meta-analysis of 28 cohort studies including adults who received aspirin.

Disclosures: This study did not report the funding source. The authors declared no conflicts of interest.

Source: Bakierzynska M et al. Prophylactic aspirin intake and breast cancer risk: A systematic review and meta-analysis of observational cohort studies. Eur J Surg Oncol. 2023 (Jun 6). doi: 10.1016/j.ejso.2023.05.015

Key clinical point: Aspirin intake may be associated with a reduced risk for incident breast cancer (BC) in adults.

Major finding: Aspirin users vs nonusers had a significantly reduced risk for BC (hazard ratio [HR] 0.91; P =  .002), especially estrogen receptor-positive BC (HR 0.90; P = .0004).

Study details: Findings are from a meta-analysis of 28 cohort studies including adults who received aspirin.

Disclosures: This study did not report the funding source. The authors declared no conflicts of interest.

Source: Bakierzynska M et al. Prophylactic aspirin intake and breast cancer risk: A systematic review and meta-analysis of observational cohort studies. Eur J Surg Oncol. 2023 (Jun 6). doi: 10.1016/j.ejso.2023.05.015

Key clinical point: Adjuvant capecitabine was extremely well tolerated in a real-world population of patients with early triple-negative breast cancer (TNBC) who had invasive residual disease at surgery after receiving neoadjuvant chemotherapy.

Major finding: The rate of treatment discontinuation due to adjuvant capecitabine-related toxicity was very low (10.4%). After a median follow-up of 15 months, the 2-year disease-free survival rate was 62.0%, and the 2- and 3-year overall survival rates were 84.0% and 76.2%, respectively.

Study details: Findings are from an observational, retrospective study including 270 patients with TNBC who had residual disease even after receiving neoadjuvant chemotherapy and were treated with adjuvant capecitabine.

Disclosures: This research was supported by Funds Ricerca Corrente 2023 from the Italian Ministry of Health. Some authors declared receiving research grants, personal fees, speaker fees, honoraria, or travel grants or having other ties with several sources.

Source: Di Lisa FS et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: Real-world evidence from CaRe, a multicentric, observational study. Front Oncol. 2023;13:1152123 (May 16). doi: 10.3389/fonc.2023.1152123

Key clinical point: Adjuvant capecitabine was extremely well tolerated in a real-world population of patients with early triple-negative breast cancer (TNBC) who had invasive residual disease at surgery after receiving neoadjuvant chemotherapy.

Major finding: The rate of treatment discontinuation due to adjuvant capecitabine-related toxicity was very low (10.4%). After a median follow-up of 15 months, the 2-year disease-free survival rate was 62.0%, and the 2- and 3-year overall survival rates were 84.0% and 76.2%, respectively.

Study details: Findings are from an observational, retrospective study including 270 patients with TNBC who had residual disease even after receiving neoadjuvant chemotherapy and were treated with adjuvant capecitabine.

Disclosures: This research was supported by Funds Ricerca Corrente 2023 from the Italian Ministry of Health. Some authors declared receiving research grants, personal fees, speaker fees, honoraria, or travel grants or having other ties with several sources.

Source: Di Lisa FS et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: Real-world evidence from CaRe, a multicentric, observational study. Front Oncol. 2023;13:1152123 (May 16). doi: 10.3389/fonc.2023.1152123

Key clinical point: Adjuvant capecitabine was extremely well tolerated in a real-world population of patients with early triple-negative breast cancer (TNBC) who had invasive residual disease at surgery after receiving neoadjuvant chemotherapy.

Major finding: The rate of treatment discontinuation due to adjuvant capecitabine-related toxicity was very low (10.4%). After a median follow-up of 15 months, the 2-year disease-free survival rate was 62.0%, and the 2- and 3-year overall survival rates were 84.0% and 76.2%, respectively.

Study details: Findings are from an observational, retrospective study including 270 patients with TNBC who had residual disease even after receiving neoadjuvant chemotherapy and were treated with adjuvant capecitabine.

Disclosures: This research was supported by Funds Ricerca Corrente 2023 from the Italian Ministry of Health. Some authors declared receiving research grants, personal fees, speaker fees, honoraria, or travel grants or having other ties with several sources.

Source: Di Lisa FS et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: Real-world evidence from CaRe, a multicentric, observational study. Front Oncol. 2023;13:1152123 (May 16). doi: 10.3389/fonc.2023.1152123